CS12088

This is a hepatitis B nucleocapsid assembly modulator exclusively discovered by the company with global patent protection. Preclinical study results demonstrated that CS12088 maintained nanomolar antiviral activity against various genotypes of hepatitis B, exhibiting liver-targeting characteristics and demonstrating favorable safety and tolerability. In February 2025, CS12088 tablets received the clinical trial approval notice.

CS12192

This is a highly selective JAK3 kinase inhibitor exclusively discovered by the company with global patent protection, which also partially inhibits JAK1 and TBK1 kinases; the indication under development is autoimmune diseases. Currently, the company has completed the Phase I clinical trial of CS12192 for rheumatoid arthritis in China.

Leveraging the company's AI-assisted design and integrated chemical genomics technology platform, the R&D pipeline is strategically focused on two major disease areas of neoplasms and metabolism, while continuously monitoring disease areas with significant unmet clinical needs such as neurodegenerative diseases and autoimmune diseases. The company has reserved a series of drug candidates with First/Best-in-class potential, such as CS08399 (a potential BIC brain-penetrant PRMT5 molecule), CS1011 (a fibrosis disease inhibitor), CDCS04 (a FIC molecule targeting the genetic risk factor ApoE4 gene for Alzheimer's disease), and CDCS28 (a non-incretin small molecule for weight loss). These projects/products will form the core value of the company in the future.